[go: up one dir, main page]

NO20052474L - Amort form av esomeprazolsalter - Google Patents

Amort form av esomeprazolsalter

Info

Publication number
NO20052474L
NO20052474L NO20052474A NO20052474A NO20052474L NO 20052474 L NO20052474 L NO 20052474L NO 20052474 A NO20052474 A NO 20052474A NO 20052474 A NO20052474 A NO 20052474A NO 20052474 L NO20052474 L NO 20052474L
Authority
NO
Norway
Prior art keywords
salts
amortized
esomeprazole
esomeprazole salts
amorphous
Prior art date
Application number
NO20052474A
Other languages
English (en)
Other versions
NO20052474D0 (no
Inventor
Yatendra Kumar
Mohan Prasad
Mahavir Singh Khanna
Bakthavathsalan Vijayaraghavan
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of NO20052474D0 publication Critical patent/NO20052474D0/no
Publication of NO20052474L publication Critical patent/NO20052474L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår en amorf form av saltene av enantiomeren av omeprazol, dvs. esomeprazol. Oppfinnelsen angår også fremgangsmåter for fremstilling av amorfe salter og farmasøytiske preparater som inkluderer de amorfe esomeprazolsaltene.
NO20052474A 2002-10-22 2005-05-23 Amort form av esomeprazolsalter NO20052474L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1057DE2002 2002-10-22
PCT/IB2003/004662 WO2004037253A1 (en) 2002-10-22 2003-10-22 Amorphous form of esomeprazole salts

Publications (2)

Publication Number Publication Date
NO20052474D0 NO20052474D0 (no) 2005-05-23
NO20052474L true NO20052474L (no) 2005-05-23

Family

ID=32170658

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052474A NO20052474L (no) 2002-10-22 2005-05-23 Amort form av esomeprazolsalter

Country Status (8)

Country Link
US (2) US20040235903A1 (no)
EP (1) EP1556043A1 (no)
CN (1) CN1728997A (no)
AU (1) AU2003278406A1 (no)
BR (1) BR0315574A (no)
EA (1) EA200500673A1 (no)
NO (1) NO20052474L (no)
WO (1) WO2004037253A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509971A (pt) * 2004-04-15 2007-10-02 Reddys Lab Inc Dr uma forma de dosagem farmacêutica, comprimido e método de preparação
EP1765806A1 (en) 2004-06-24 2007-03-28 AstraZeneca AB New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1827429A4 (en) * 2004-12-20 2009-08-05 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS BENZIMIDAZOLE COMPOUNDS
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
DE102005008412A1 (de) * 2005-02-24 2006-09-07 Ratiopharm Gmbh Piperazinsalz des Omeprazols und dessen Enantiomere
WO2006096709A2 (en) * 2005-03-08 2006-09-14 Dr. Reddy's Laboratories Ltd. Process for preparing amorphous salts
WO2007008588A2 (en) * 2005-07-07 2007-01-18 Dr. Reddy's Laboratories Ltd. Omeprazole form b
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
WO2007054951A1 (en) * 2005-11-14 2007-05-18 Hetero Drugs Limited Process for amorphous esomeprazole
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP1960384A4 (en) * 2005-12-05 2010-03-24 Astrazeneca Ab NOVEL PROCESS FOR THE PRODUCTION OF NON-SALINE ESOMEPRAZOLE
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CA2653429A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Novel method for preparation of ammonium salts of esomeprazole
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
KR101522865B1 (ko) 2007-02-21 2015-05-26 시플라 리미티드 에소메프라졸 마그네슘 2수화물의 형태 a의 제조방법
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2011095984A1 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited A process for the preparation of amorphous esomeprazole
FR3062129B1 (fr) * 2017-01-23 2019-04-05 Minakem Procede d'obtention du sel de magnesium dihydrate de l'esomeprazole
CN113387929A (zh) * 2021-06-30 2021-09-14 江苏中邦制药有限公司 一种艾司奥美拉唑镁三水合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5714505A (en) * 1994-01-05 1998-02-03 Astra Aktiebolag Method for treatment of psoriasis, by omeprazole or related compounds
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6124816A (en) * 1998-06-02 2000-09-26 Cirrus Logic, Inc. One bit digital to analog converter with relaxed filtering requirements
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
BR0110926A (pt) * 2000-05-15 2004-02-17 Ranbaxy Lab Ltd Novas formas amorfas de sais de omeprazol e processo de preparação dos mesmos
ATE342263T1 (de) * 2000-08-04 2006-11-15 Takeda Pharmaceutical Salze von benzimidazol-derivaten und deren verwendung
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
KR100914175B1 (ko) * 2001-07-16 2009-08-27 얀센 파마슈티카 엔.브이. 벤즈이미다졸-타입 화합물의 개선된 제조 방법
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
US7651788B2 (en) * 2003-03-05 2010-01-26 Lg Display Co., Ltd. Organic electroluminescent device

Also Published As

Publication number Publication date
US7482463B2 (en) 2009-01-27
US20080119654A1 (en) 2008-05-22
BR0315574A (pt) 2005-09-20
CN1728997A (zh) 2006-02-01
EA200500673A1 (ru) 2005-12-29
AU2003278406A1 (en) 2004-05-13
NO20052474D0 (no) 2005-05-23
WO2004037253A1 (en) 2004-05-06
US20040235903A1 (en) 2004-11-25
EP1556043A1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
NO20052474L (no) Amort form av esomeprazolsalter
IS6902A (is) N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl
SE0203713D0 (sv) Novel compounds
NO20056130L (no) Nye substituerte 3-svovelindoler
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
WO2005046603A3 (en) Pyridine compounds
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
DK1421075T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
NO20060717L (no) Sykliske derivater som modulatorer av kjemokin reseptoractivitet
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
NO20045589L (no) Nye forbindelser
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
NO20080967L (no) Benzimidazoler nyttige som inhibitorer av proteinkinaser
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
DK1879580T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
DK1434588T3 (da) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)aminoalkylsyrederivater til behandling af smerte